Research groups
Colleges
DPhil projects available
AKR1C1 as a therapeutic target in non-alcholoic fatty liver diease and hepatocellular carcinoma
Jeremy Tomlinson
MB BCh, PhD, FRCP
Professor of Metabolic Endocrinology
My work tries to better understand and treat metabolic diseases, in particular, non-alcholic fatty liver disease (NAFLD). Our work has focused on the role of steroid hormones and their metabolism in the development, assessment and treatment of metabolic diseases including NAFLD, obesity and type 2 diabetes. Our previous work has shown that altering steroid hormone metabolism can have a potent impact on the function of both liver and adipose tissue to store fat. Our future work will use steroid biomarkers not only to stage disease severity, but to predict progression. In addition, by altering tissue specific-metabolism, we hope to limit the side effects of prescribed steroids.
Key publications
-
Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man.
Journal article
Hazlehurst JM. et al, (2016), J Clin Endocrinol Metab, 101, 103 - 113
-
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
Journal article
Armstrong MJ. et al, (2016), J Hepatol, 64, 399 - 408
-
5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes.
Journal article
Nasiri M. et al, (2015), Endocrinology, 156, 2863 - 2871
Recent publications
-
Peri-operative corticosteroid supplementation for patients on therapeutic glucocorticoids: a national survey.
Journal article
Ramesh AV. et al, (2020), Anaesthesia
-
Editorial: can urine-based metabolomics improve diagnosis of advanced fibrosis in NAFLD? Authors' reply.
Journal article
Moolla A. and Tomlinson JW., (2020), Aliment Pharmacol Ther, 51, 1205 - 1206
-
Sodium-glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes.
Journal article
Marjot T. et al, (2020), JGH Open, 4, 433 - 440
-
Altered cortisol metabolism in individuals with HNF1A-MODY.
Journal article
Juszczak A. et al, (2020), Clin Endocrinol (Oxf)
-
Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome.
Journal article
Moolla A. et al, (2020), Aliment Pharmacol Ther